Evidence map›Paper›PMID 27489646›Full record

ArticleSAGE open medical case reports2014

Fatal case of cephalexin-induced toxic epidermal necrolysis.

Matthew J Hafermann, Gerard R Barber, Stephen C Dreskin, Gordon K Lindberg

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Matthew J HafermannUniversity of Washington Medical Center, Seattle, WA, USA.
Gerard R BarberDepartment of Pharmacy Services, University of Colorado Hospital, Aurora, CO, USA; School of Pharmacy, University of Colorado, Aurora, CO, USA.
Stephen C DreskinAllergy, Asthma, and Immunology Practice, University of Colorado Hospital; School of Medicine, University of Colorado, Aurora, CO, USA.
Gordon K LindbergUniversity of Colorado Hospital, Aurora, CO, USA; Surgery-GI Tumor and Endocrine Surgery, School of Medicine, University of Colorado, Aurora, CO, USA.
University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · USUniversity of Colorado Hospital · USUniversity of Washington Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe a case of toxic epidermal necrolysis likely caused by cephalexin with a review of the literature. CASE: An 80-year-old male with a known allergy to cephalosporins, residing at a long-term acute care hospital, received cephalexin for a urinary tract infection. And 1 day after starting therapy, the patient developed an extensive erythematous rash accompanied by skin sloughing; 4 days after receiving cephalexin, the patient was directly admitted to the burn intensive care unit and was diagnosed with toxic epidermal necrolysis involving 56% of the total body surface area. Progressive deterioration to multisystem organ failure ensued, and the patient died 5 days following his admission to the burn intensive care unit. At the time of death, ulcerations were noted over approximately 80% of his body. SUMMARY: The temporal association of the patient's ingestion of cephalexin for a urinary tract infection to his onset of toxic epidermal necrolysis suggests that this 80-year-old man developed toxic epidermal necrolysis following the administration of cephalexin for a urinary tract infection.

Indexed as

allergic reactiondrugsrashStevens–Johnson syndrome

Identifiers

PMID27489646
PMCPMC4857339
OpenAlexW2105205635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.